Community curated by people like you

Piper sandler stories

Nov 13, 2026

Windward Bio prices $175M IPO to advance China-licensed lung drugs

Swiss immune drug developer Windward Bio raised $175 million in its IPO, the biotech sector's 30th listing of the year, to advance lung disease drugs licensed from China.

Nov 13, 2026·2 sources

00

Top claims

▪Sanofi purchased $50 million of shares and pre-funded warrants in a private stock placement concurrent with Windward Bio's initial public offering
▪Windward Bio begins trading on November 13, 2026 under the ticker symbol WWB
▪Biopharmaceutical initial public offerings have raised over $8 billion in 2026, marking the sector's busiest IPO year since 2021

Topics

Biotechnology Asthma Respiratory diseases Pharmaceutical Industry Drug development Clinical trials Biotech innovation COPD

Related entities

Nasdaq Switzerland China